Voyager Therapeutics (VYGR) Current Deferred Revenue (2014 - 2026)

Voyager Therapeutics has disclosed Current Deferred Revenue across 13 years of filings, most recently posting $395000.0 for Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $395000.0, down 98.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $395000.0 (down 98.13% YoY), and the FY2025 annual result was $1.6 million, down 93.48% from the prior year.
• Current Deferred Revenue came in at $395000.0 for Q1 2026 at Voyager Therapeutics, down from $1.6 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $87.0 million in Q2 2022 to a low of $395000.0 in Q1 2026.
• The 5-year median for Current Deferred Revenue is $22.6 million (2024), against an average of $30.1 million.
• Across the five-year window, Current Deferred Revenue soared 805.62% in 2024 and slumped 98.13% in 2026, its largest moves.
• Voyager Therapeutics' Current Deferred Revenue stood at $59.4 million in 2022, then declined by 27.78% to $42.9 million in 2023, then tumbled by 43.11% to $24.4 million in 2024, then slumped by 93.48% to $1.6 million in 2025, then slumped by 75.16% to $395000.0 in 2026.
• The last three Current Deferred Revenue figures came in at $395000.0 (Q1 2026), $1.6 million (Q4 2025), and $10.6 million (Q3 2025), per Business Quant data.